Comparison of Methadone and Morphine in the Treatment of Neonatal Abstinence Syndrome Based on Treatment Duration

AuthorAli Nasehen
AuthorKosar Noorzadehen
AuthorGhazaleh Rastien
AuthorFarzaneh Palizbanen
AuthorFarhad Mansourien
AuthorMarzieh Maddahen
AuthorNaeeme Taslimi Taleghanien
AuthorElahe Rastkar Mehrabanien
AuthorSadaf Hasanien
OrcidAli Naseh [0000-0001-7258-0815]en
OrcidKosar Noorzadeh [0009-0000-7587-7251]en
OrcidGhazaleh Rasti [0009-0009-2617-7430]en
OrcidFarzaneh Palizban [0000-0002-4127-9541]en
OrcidFarhad Mansouri [0009-0006-2383-5248]en
OrcidMarzieh Maddah [0000-0002-4186-9584]en
OrcidNaeeme Taslimi Taleghani [0000-0003-4924-2310]en
OrcidElahe Rastkar Mehrabani [0009-0001-3632-6569]en
OrcidSadaf Hasani [0009-0008-5358-8422]en
Issued Date2026-11-30en
AbstractBackground: Neonatal abstinence syndrome is a major consequence of in utero opioid exposure. Objectives: This study compared methadone and morphine for controlling NAS and assessed their effects on treatment duration. Methods: This prospective comparative clinical trial with alternating allocation was conducted at Mahdiyeh Hospital in 2024 - 2025. Neonates with a gestational age of ≥ 34 weeks who were diagnosed with NAS were assigned to a treatment group. Pharmacologic treatment was initiated when two assessments performed 3 - 4 hours apart yielded Finnegan scores ≥ 8. Neonates with major congenital anomalies were excluded. Treatment duration was measured until treatment cessation. Results: Of 158 neonates, 89 received methadone (mean treatment duration, 19.3 days; median, 17 days; range, 7 - 50 days), and 69 received morphine (mean treatment duration, 21.2 days; median, 20 days; range, 8 - 51 days). Variability was high in both groups, with standard deviations of 9.1 days for methadone and 10 days for morphine. The unadjusted independent-samples t-test showed that treatment lasted an average of 1.9 days longer in neonates receiving morphine; however, the difference was not statistically significant (P = 0.212). In the primary multivariable analysis, which was adjusted for gestational age, birth weight, milk intolerance, and polysubstance exposure but not phenobarbital use, morphine was associated with an estimated 2.05-day longer treatment duration than methadone; this difference was not statistically significant (β = 2.05 days; 95% confidence interval [CI], −1.29 to 5.40; P = 0.229). In a sensitivity analysis additionally adjusted for phenobarbital use, the estimated treatment effect was attenuated and reversed in direction (β = −0.34 days; 95% CI, −3.70 to 3.01; P = 0.841). None of the covariates in the primary model, including gestational age, was independently associated with treatment duration (P > 0.05). Adjunctive phenobarbital use was associated with longer treatment duration. Sex was not associated with treatment duration and was not retained as a significant predictor. Conclusions: No statistically significant difference in treatment duration was observed between methadone and morphine for NAS.en
DOIhttps://doi.org/10.5812/jcp-174053en
URIhttps://brieflands.com/journals/jcp/articles/174053en
KeywordNeonatal Abstinence Syndromeen
KeywordMethadoneen
KeywordMorphineen
KeywordOpioid Withdrawalen
KeywordNewbornen
PublisherBrieflandsen
TitleComparison of Methadone and Morphine in the Treatment of Neonatal Abstinence Syndrome Based on Treatment Durationen
TypeResearch Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
jcp-17-4-174053-publish-pdf.pdf
Size:
481.37 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF